- Edwards Lifesciences press release ( NYSE: EW ): Q4 Non-GAAP EPS of $0.64 beats by $0.03 .
- Revenue of $1.35B (+1.5% Y/Y) beats by $20M .
- Shares +2.3% .
- Q4 TAVR sales were flat; constant currency sales grew 5 percent
- Overall, the company is reaffirming the sales guidance it provided at the December investor conference for all product groups. Full year 2023 sales are expected to grow 9 to 12 percent to $5.6 to $6.0 billion. Additionally, the company continues to expect full year 2023 adjusted earnings per share of $2.45 to $2.60 vs. $2.50 consensus
- For the first quarter of 2023, the company projects total sales to be between $1.37 and $1.45 billion, and adjusted EPS of $0.58 to $0.64.
For further details see:
Edwards Lifesciences Non-GAAP EPS of $0.64 beats by $0.03, revenue of $1.35B beats by $20M